Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11702792 | 0.97 | — | — | |
| SCHEMBL821855 | 0.97 | — | — | |
| SCHEMBL486034 | 0.75 | ESR1 (0.36) | KDM1A | |
| SCHEMBL31097915 | 0.73 | — | — | |
| SCHEMBL6249683 | 0.72 | CYP19A1 (0.32) | — | |
| SCHEMBL6249751 | 0.72 | CYP19A1 (0.32) | — | |
| SCHEMBL3304813 | 0.70 | — | — | |
| SCHEMBL9430980 | 0.70 | MAPT (0.40) | — | |
| SCHEMBL5378612 | 0.67 | — | — | |
| SCHEMBL11817035 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS INCORPORATED | 2021-05-06 | — | — | US | claimed |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2014-01-02 | — | — | US | claimed |
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2306830-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Corcept Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2010-07-15 | — | — | US | claimed |
| WO-2010002901-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| EP-2012796-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | Corcept Therapeutics, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007131041-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| EP-2576582-B1 | TREATMENT OF MUSCULAR DYSTROPHY | CORCEPT THERAPEUTICS INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2576582-A1 | TREATMENT OF MUSCULAR DYSTROPHY | Corcept Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150209-A1 | TREATMENT OF MUSCULAR DYSTROPHY | CORCEPT THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294771-A1 | TREATMENT OF MUSCULAR DYSTROPHY | CORCEPT THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| EP-2012796-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | Corcept Therapeutics, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007131041-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRHR1, NR3C1, CRH | KDM1A 3614/4885 |
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CRHR2, IL2, GRIA2 | KDM1A 4385/4885 |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRHR1, NR3C1, CRH | KDM1A 3614/4885 |
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NR3C1, CRHR1, NR3C2 | KDM1A 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.